2021 Vault Rankings
At a Glance
“Growth opportunity, culture, flexibility.”
“Platform to develop your own personal brand.”
“Lack of oversight and formal mentoring.”
“Processes and infrastructure still being built out.”
“Small size, so people wear multiple hats.”
About DeciBio Consulting
DeciBio Consulting is a boutique strategy consulting firm focusing on the life science industry. DeciBio's mission is to provide the strategic insights that accelerate the adoption of precision medicine.
Headquartered in Los Angeles, CA, DeciBio serves clients and customers across the globe, ranging from incubator-stage startups to Fortune 500 life science corporations. DeciBio addresses business solutions that range from market landscape analyses to full commercial strategies, including organic and inorganic growth opportunities (commercial due diligences). The work is typically supported by a mix of primary and secondary research leveraging its in-house expert network (“Dexter”).
In the News
September 2020 – DeciBio Analytics launches Dexter, an expert network marketplace for the life science industry
DeciBio Analytics, the market intelligence subsidiary of DeciBio Consulting, has launched an expert network marketplace named Dexter. The launch follows Dexter’s successful beta release a year ago. Dexter customers receive market intelligence by leveraging Dexter’s life science expert network for 1:1 interviews and pulse surveys. Dexter offers an end-to-end research project solution, from finding relevant experts and scheduling interviews, to processing payments. The Dexter network spans various life science cohorts including - but not limited to - single-cell genomics, liquid biopsy, pathology, proteomics, and oncology.
September 2020 – DeciBio Consulting Launches Emmes SARS-CoV-2 Testing Database
DeciBio Consulting has launched the Emmes SARS-CoV-2 Testing Database. This Database serves as the latest addition to the market intelligence products already under DeciBio Consulting’s umbrella. Such products include the Emmes Infectious Disease Database, the Emmes Oncology Database, BioMAP (immuno-oncology biomarkers), Marketbooks, Dexter, and BioTrack, among others.
The DeciBio Emmes SARS-CoV-2 Testing Database provides data visualization tools and raw data covering coronavirus testing practices in approximately 400 labs in the United States. This data includes diagnostic and serology testing details at hospital, public health, and commercial reference labs, as well as send-out volumes. This Database aims to provide insights into current testing behavior and trends to measure how the testing industry is responding to the pandemic.
August 2019: DeciBio expands parental support and professional development benefits
DeciBio has introduced new benefits that offer custom-tailored enrichment opportunities and support for employees. Highlights include:
- The DeciBio “Intrapreneurship” Program provides eligible employees with customized professional development opportunities via “pet projects” and inter-company experiences throughout the world.
- DeciBio’s Parental Support policies support all parents (regardless of gender) as they welcome the birth or adoption of a child. Eligible employees will receive their full salary during the first twelve weeks of any new parent leave. Further, employees will receive their full salary during the first four weeks of any pregnancy disability leave taken during their pregnancy. And, based on each new parent’s unique needs, DeciBio will work with the employee to create a supportive work environment via, e.g., flexibility, part-time employment opportunities, work-from-home opportunities, and wellness room accessibility.
July 2019: DeciBio Consulting acquires diagnostic database products from The Emmes Group
DeciBio announced the acquisition of the Emmes Group’s diagnostic database products. The Emmes Group’s diagnostic database products will provide DeciBio with valuable real-world market intelligence to support DeciBio’s mission to provide market intelligence and strategic insights that drive disruption and innovation in the precision medicine industry. The Emmes MDx Database provides metrics for the most relevant molecular tests and test panels across 1,000 U.S. MDx testing labs. Emmes Oncology Database offers similar customer level information focused on tissue-based testing in 300 U.S. anatomic pathology labs.
April 2019: DeciBio welcomes Andrew Aijian, Ph.D., as Partner
At DeciBio, Andrew advises clients on the activities, strategies, and opportunities accompanying the emergence of cancer immunotherapies and has actively expanded DeciBio’s pharma and biotech practice. Andrew has led projects across a wide variety of segments within the research tools and clinical diagnostics landscapes, including, among others, infectious disease diagnostics, health IT, translational pathology, genomics instruments and reagents, proteomics research tools, and oncology diagnostics and biomarkers. He has also contributed to multiple market research reports, developed DeciBio’s clinical trial biomarker analysis platform (BioMAP), and advised on the spin-out of DeciBio Analytics. Andrew first joined DeciBio in 2013, as a Ph.D. intern.
10203 Santa Monica Blvd
Los Angeles, CA 90067
Phone: (310) 451-4510
Employer Type: Private
Partner: Stephane Budel
Partner: David Cavanaugh
Partner: Andrew Aijian
2020 Employees (All Locations): 50
Los Angeles, CA
San Francisco, CA
Life Science Research Tools
Digital Health and Patient Health Technologies
Commercial Due Diligence and Portfolio Support